Saturday, 5 September 2026European Markets

NYRSTAR Stock Went Up By Over 24% In The Last 10 Sessions

Loading stream...

(VIANEWS) - Shares of NYRSTAR (BEL 20: NYR.BR) rose by a staggering 24.03% in 10 sessions from €0.13 to €0.16 at 14:22 EST on Tuesday, after four successive sessions in a row of gains. BEL 20 is jumping 0.64% to €3,529.65, after two consecutive sessions in a row of gains.

NYRSTAR's last close was €0.16, 36.35% under its 52-week high of €0.25.

About NYRSTAR

Nyrstar NV does not have significant operations. Previously, it was engaged in the mining, smelting, and producing of zinc, lead, and other base and precious metals primarily in Europe, Australia, Canada, and the United States. Nyrstar NV was founded in 2007 and is based in Balen, Belgium.

Earnings Per Share

As for profitability, NYRSTAR has a trailing twelve months EPS of €-0.01.

Volatility

NYRSTAR's last week, last month's, and last quarter's current intraday variation average was 5.51%, 1.58%, and 2.91%.

NYRSTAR's highest amplitude of average volatility was 5.51% (last week), 2.59% (last month), and 2.91% (last quarter).

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, NYRSTAR's stock is considered to be oversold (<=20).

More news about NYRSTAR (NYR.BR).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Capital Surge Meets Investor Caution: Record Funding Rounds and Government Contracts Amid Valuation Skepticism
A single-week cluster of large AI/fintech funding rounds (Socure, Stability AI, Emerald AI, Generalist AI, Instinct, Gatik, Regent Craft) shows venture capital still pouring into AI infrastructure, identity, and autonomy plays, while Palantir's Army TITAN contract win coincided with a 6% stock drop — signaling that even flagship AI-defense revenue isn't immune to market reassessment of AI valuations. Efficiency-focused innovations like Multiverse Computing's model compression suggest the sector is also pivoting toward cost/inference economics as capital intensity draws scrutiny.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Morgan Stanley & Co. LLC
The same metric (eps) for the same entity (Morgan Stanley & Co. LLC) reported for the identical fiscal period (Q1 2026) and observation date (2026-03-31) has two conflicting values: 3.43 USD_per_share vs 3.08 USD. This is not a temporal change — both observations claim to measure the same point in time. The ~10% discrepancy (0.35 USD difference) is material for a financial metric.
We flag conflicts openly ›
Recently verified
Checked against the original source
4,981
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,981 facts checked against source5,273 source documents archived
Query this data → isubstrate.com